Premium
High‐density lipoproteins in high resolution: Will proteomics solve the paradox for cardiovascular risk?
Author(s) -
Baig Ferheen,
Joshi Abhishek,
Mayr Manuel
Publication year - 2017
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201600426
Subject(s) - dyslipidemia , myocardial infarction , proteomics , informatics , high density lipoprotein , population , high resolution , medicine , lipoprotein , computer science , cholesterol , risk analysis (engineering) , bioinformatics , computational biology , diabetes mellitus , endocrinology , biology , engineering , environmental health , biochemistry , electrical engineering , gene , remote sensing , geology
While lipid abnormalities continue to account for over 60% of the population attributable risk for myocardial infarction, the well‐known inverse correlation between plasma high‐density lipoprotein (HDL) cholesterol and cardiovascular risk has failed to deliver clinically useful therapeutic interventions. Thus, there is an unmet need to better understand the function of different HDL particles. Targeted, high‐resolution lipoproteomics provides an innovative approach to studying the kinetics of HDL particles. In this commentary, we discuss the development of an informatics platform for increased throughput and highlight how this approach delivers the potential for novel, hybrid instrument technologies to inform clinical dyslipidemia studies.